Drugs / NNC0537-1482
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07218627 | Oct 2025 → Jan 2027 expected | heart failure | Novo Nordisk A/S | Recruiting | No outcome recorded |
| Phase 1 | NCT06625307 | Oct 2024 → May 2025 | heart failure | Novo Nordisk A/S | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NNC0537-1482 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06625307 ↗ |
| Route | Subcutaneous | “Administered via subcutaneous route” NCT06625307 ↗ |